Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.
Duchnowska R, Sperinde J, Czartoryska-Arłukowicz B, Myśliwiec P, Winslow J, Radecka B, Petropoulos C, Demlova R, Orlikowska M, Kowalczyk A, Lang I, Ziółkowska B, Dębska-Szmich S, Merdalska M, Grela-Wojewoda A, Żawrocki A, Biernat W, Huang W, Jassem J.
Duchnowska R, et al.
Oncotarget. 2017 Oct 24;8(61):104149-104159. doi: 10.18632/oncotarget.22027. eCollection 2017 Nov 28.
Oncotarget. 2017.
PMID: 29262628
Free PMC article.